Early Morning Insight: Arena Pharmaceuticals, Geron, Celgene, Incyte, and Spectrum Pharmaceuticals

LONDON, June 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Monday, June 24, 2013, shares in biotechnology companies ended on a mixed note even as the broader market fell sharply amid concerns over the Federal Reserve's bond buying program and a possible liquidity crisis in China. The major movers in the biotechnology sector on Monday included Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Geron Corporation (NASDAQ: GERN), Celgene Corporation (NASDAQ: CELG), Incyte Corporation (NASDAQ: INCY), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on ARNA, GERN, CELG, INCY, and SPPI now at

http://www.aaaresearchreports.com/register/

Shares in Arena Pharmaceuticals Inc. moved higher on Monday even as the broader market took a plunge. The company's shares traded between $7.82 and $8.29 before finishing the day 1.12% higher at $8.14. A total of 6.30 million shares were traded which is above the daily average volume of 5.75 million. Arena's shares have gained 6.96% in the last three trading sessions. Download free research on ARNA today by registering at:

http://www.AAAResearchReports.com/ARNA062513.pdf

Geron Corporation's stock rose on Monday, extending its gains from previous trading sessions. The company's shares hit an intraday high of $1.23 before finishing the day 0.83% higher at $1.22. A total of 1.09 million shares were traded which is above the daily average volume of 918,096. Geron's shares have jumped 2.52% in the last three trading sessions. In the previous three months, the stock has risen 10.91%, thus outperforming the S&P 500. Sign up and have access to our free report on GERN at:

http://www.AAAResearchReports.com/GERN062513.pdf

Shares in Celgene Corporation slipped on Monday, extending their losses from previous trading sessions. The company's shares ended the day 0.78% lower at $113.00 after trading between $110.53 and $114.84. A total of 3.33 million shares were traded which is slightly above the daily average volume of 3.21 million. Additionally, the stock is trading below its 50-day moving average of $121.03. Sign up and read the complimentary report on CELG at:

http://www.AAAResearchReports.com/CELG062513.pdf

Incyte Corporation's stock rose sharply on Monday, reversing some of its recent losses. The company's shares traded between $18.23 and $19.60 before ending the day 1.47% higher at $19.35. A total of 1.29 million shares were traded which is slightly above the daily average volume of 1.28 million. Incyte's shares have fallen 4.96% in the last three trading sessions. The free report on INCY can be downloaded by signing up now at:

http://www.AAAResearchReports.com/INCY062513.pdf

Shares in Spectrum Pharmaceuticals Inc. slipped on Monday, tracking losses in the broader market. The company's shares closed the day at $7.90, down 1.37%, after hitting an intraday low of $7.20. A total of 2.03 million shares were traded which is more than double the daily average volume of 968,498. However, despite the recent losses, the stock is still up 11.88% in the last three months. Free report on SPPI can be accessed by registering at

http://www.AAAResearchReports.com/SPPI062513.pdf

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED